Serologic response in human papillomavirus-associated invasive cervical cancer - PubMed (original) (raw)
. 1993 Nov 11;55(5):780-4.
doi: 10.1002/ijc.2910550515.
Affiliations
- PMID: 8244575
- DOI: 10.1002/ijc.2910550515
Serologic response in human papillomavirus-associated invasive cervical cancer
R P Viscidi et al. Int J Cancer. 1993.
Abstract
Human papillomavirus (HPV) transforming proteins E6 and E7 are uniformly expressed in HPV-associated cervical cancer. Our objective was to measure antibodies to HPV-16 E6 and E7 proteins in cervical cancer patients using an assay which would detect antibodies to conformational epitopes. Serum specimens obtained from two case-control studies of HPVs and cervical cancer were tested. The studies were performed in Cali, Colombia, South America and in 9 provinces of Spain. Cases consisted of women with invasive cervical cancer associated with HPV-16 or other HPV types and women with HPV-16-associated high-grade cervical intra-epithelial neoplasia (CIN-3). Controls for invasive cases and CIN-3 cases were women who had no cytologic abnormalities and who were matched for age and country of residence. Serum antibodies to HPV-16 E6 and E7 proteins were detected by radio-immunoprecipitation of in vitro translated proteins. Antibodies to the E6 and E7 protein were observed among 56% and 43%, respectively, of invasive cases and 1.7% and 4.1%, respectively, of controls. Antibodies to either protein were detected in 72% of sera from invasive cases and 5.8% of sera from controls. High antibody reactivity and antibodies to both proteins were found almost exclusively in invasive cases. The frequency of antibodies to the E6 protein and the E7 protein among CIN-3 cases did not differ significantly from the CIN-3 controls. Five women with HPV-18-associated invasive cervical cancer were negative for serum antibody to HPV-16 E6 and E7 proteins. Antibodies to HPV-16 E6 and E7 proteins appear to be partially virus-specific and disease state-specific markers of HPV-associated cervical cancer.
Similar articles
- Profiling of serum antibodies against human papillomavirus antigens in Korean women with cervical intraepithelial neoplasia and cervical cancer.
Jin Y, Choi JW, Kim HJ, Eddouzi J, Kim SC, Ju W, Kim YH, Kim HJ. Jin Y, et al. Cancer Med. 2018 Nov;7(11):5655-5664. doi: 10.1002/cam4.1810. Epub 2018 Oct 23. Cancer Med. 2018. PMID: 30353680 Free PMC article. - Immunologic diagnosis and monitoring of cervical cancers using in vitro translated HPV proteins.
Chee YH, Namkoong SE, Kim DH, Kim SJ, Park JS. Chee YH, et al. Gynecol Oncol. 1995 May;57(2):226-31. doi: 10.1006/gyno.1995.1130. Gynecol Oncol. 1995. PMID: 7729739 Clinical Trial. - Usefulness of high-risk HPV early oncoprotein (E6 and E7) serological markers in the detection of cervical cancer: A systematic review and meta-analysis.
Singini MG, Singh E, Bradshaw D, Ramaliba T, Chen WC, Motlhale M, Kamiza AB, Babb de Villiers C, Muchengeti M, Mathew CG, Newton R, Bender N, Waterboer T, Sitas F. Singini MG, et al. J Med Virol. 2023 Jan;95(1):e27900. doi: 10.1002/jmv.27900. Epub 2022 Jun 9. J Med Virol. 2023. PMID: 35641882 Free PMC article. Review. - Immunotherapy that leverages HPV-specific immune responses for precancer lesions of cervical cancer.
Kobayashi O, Taguchi A, Nakajima T, Ikeda Y, Saito K, Kawana K. Kobayashi O, et al. Taiwan J Obstet Gynecol. 2024 Jan;63(1):22-28. doi: 10.1016/j.tjog.2023.10.002. Taiwan J Obstet Gynecol. 2024. PMID: 38216264 Review.
Cited by
- HPV types 16/18 L1 E6 and E7 proteins seropositivity and cervical cancer risk in HIV-positive and HIV-negative black South African women.
Singini MG, Singh E, Bradshaw D, Chen WC, Motlhale M, Kamiza AB, de Villiers CB, Muchengeti M, Mathew CG, Newton R, Bender N, Waterboer T, Sitas F. Singini MG, et al. Infect Agent Cancer. 2022 Mar 29;17(1):14. doi: 10.1186/s13027-022-00418-2. Infect Agent Cancer. 2022. PMID: 35351184 Free PMC article. - Invited commentary: Biological and clinical insights from epidemiologic research into HIV, HPV, and anal cancer.
Engels EA, Madeleine MM. Engels EA, et al. Am J Epidemiol. 2013 Sep 15;178(6):885-7. doi: 10.1093/aje/kwt149. Epub 2013 Jul 30. Am J Epidemiol. 2013. PMID: 23900552 Free PMC article. - Combined p53-related genetic variants together with HPV infection increase oral cancer risk.
Wang Z, Sturgis EM, Zhang Y, Huang Z, Zhou Q, Wei Q, Li G. Wang Z, et al. Int J Cancer. 2012 Aug 1;131(3):E251-8. doi: 10.1002/ijc.27335. Epub 2011 Dec 2. Int J Cancer. 2012. PMID: 22052649 Free PMC article. - A novel HPV 16 L1-based chimeric virus-like particle containing E6 and E7 seroreactive epitopes permits highly specific detection of antibodies in patients with CIN 1 and HPV-16 infection.
Monroy-García A, Gómez-Lim MA, Weiss-Steider B, la Rosa GP, Hernández-Montes J, Pérez-Saldaña K, Tapia-Guerrero YS, Toledo-Guzmán ME, Santiago-Osorio E, Sanchez-Peña HI, Mora-García Mde L. Monroy-García A, et al. Virol J. 2011 Feb 9;8:59. doi: 10.1186/1743-422X-8-59. Virol J. 2011. PMID: 21306638 Free PMC article. - High-throughput profiling of the humoral immune responses against thirteen human papillomavirus types by proteome microarrays.
Luevano M, Bernard HU, Barrera-Saldaña HA, Trevino V, Garcia-Carranca A, Villa LL, Monk BJ, Tan X, Davies DH, Felgner PL, Kalantari M. Luevano M, et al. Virology. 2010 Sep 15;405(1):31-40. doi: 10.1016/j.virol.2010.05.011. Epub 2010 Jun 15. Virology. 2010. PMID: 20554302 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical